News

As part of the transaction, Michael Ross, managing partner at SV Life Sciences, and Joseph Amprey, senior managing director of MedImmune Ventures, joined the NKT Therapeutics board. NKT

Durezol, developed and marketed by Sirion Therapeutics, was previously approved by the FDA for the treatment of post-operative inflammation and pain associated with ocular surgery. The supplemental application

According to Genzyme Canada, Synvisc-One is the latest addition to its Synvisc family of products used to treat osteoarthritis including: a single 2ml injection for the hip, shoulder

The agreement resolves litigation that was pending in the US District Court of Texas with respect to certain Medtronic products.

The company has streamlined its operations through a series of initiatives designed to reduce annual expenses by approximately $3.5 million to a current operating burn rate of approximately

The consideration comprises of $3 million paid in cash to PHC at closing and additional payments totaling $2 million that are contingent upon Pivotal Research Group achieving certain

According to Cordis, Nevo is the first and only drug-eluting stent utilizing a unique reservoir technology, which Cordis acquired from Conor Medsystems in 2007, and incorporates hundreds of

As the company’s chief science officer/chief medical officer, Mr Chew will establish a unified medical voice for Sanofi-Aventis US among internal and external stakeholders. Mr Chew will be

A randomized, double-blind, placebo-controlled, three-way cross-over study was conducted in 108 seasonal allergic rhinitis (SAR) patients to compare the relative efficacy of Captisol-Enabled budesonide + azelastine nasal spray